HPNE introduces defined tubing routing for single-use facilities
Flexible support system simplifies and secures tubing paths for biopharmaceutical manufacturers.
High Purity New England (HPNE), a supplier of biopharma equipment and process systems has launched its new line of defined tubing routing (DTR), a flexible tubing support system targeted for single-use biopharmaceutical manufacturing.
This modular system holds silicon tubing securely, eliminating dips and preventing dips that occur in unsupported pressurized lines.
For the first time, skid builders, process engineers, and facilities managers have a proven, mass-produced, and versatile option specifically engineered to define supported and clean routing of single-use tubing.
DTR simplifies single-use tubing management in a cleanroom environment, with colour-coded rigid supports for easy visual identification of each tube connection.
With solid and supported bridges, even over short spans, it securely holds any length of single-use tubing.
The combination of clips and routes are mounted to brackets to provide rigid and secure support, even over long tube runs.
Portable mounting panels can be engineered to get tubing off the floor without damaging cleanroom walls.
Megan Baillie, Product Specialist at HPNE, described DTR as a “simple solution to a ubiquitous problem". She added: “Skid builders will love the versatility of this product as it can be modified for different needs, including attaching to walls, chromatography columns, and exfiltration systems.”
DTR comes in 2.9-m length, fits a wide range of clips and standard tubing sizes (6 mm–19 mm) and comes in many colours.
As the US facility installer, HPNE can customize DTR for a variety of applications, including for new builds and retrofitted into existing single-use facilities; improved aesthetic to ensure a process appears organized and secure for virtual inspections; and reduced human error and trip hazards.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...